C03DB01 amiloride
CARDIOVASCULAR SYSTEM ›DIURETICS ›ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS ›Other potassium-sparing agents
健保收載品項 FDA 已核准 TFDA 在效許可證 3 健保給付條款 2
健保收載品名:"瑞士"壓得平錠5公絲(阿米諾樂)、保甲利壓錠5毫克、高路利錠
FDA 適應症
INDICATIONS AND USAGE Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliureticdiuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic. prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes.
資料來源:openFDA(美國 FDA Structured Product Labeling)。為英文原文,僅供對照。
TFDA 適應症
NHI 給付規定
直接適用條款
§ 2.9.2 Amiloride 單方口服製劑(109/9/1)
心臟血管及腎臟藥物 › 利尿劑
Amiloride單方口服製劑(109/9/1) 1.限Liddle's Syndrome病人經事前審查核准後使用。 2.送審時須檢附高血壓、血液電解質異常(高血鈉、低血鉀),酸鹼度偏鹼(如高serum bicarbonate)、血液醛固酮(aldosterone)偏低或正常濃度及低血液renin activity之病歷資料。
歷史演變(1 次異動)
| 生效日 | 異動說明 |
|---|---|
| 109/9/1 | legacy_boan_parsed:ch02.txt |
上層 ATC 繼承條款
繼承自 ATC C03
§ 2.9 利尿劑
心臟血管及腎臟藥物 › 利尿劑
利尿劑 (Diuretics)
實證補充
本藥品尚無實證補充整理(未來新增 Review/指引知識時補列)。
FDA 段:openFDA US SPL · TFDA 段:食藥署西藥許可證+ATC 分類開放資料 · NHI 段:健保署「全民健康保險藥品給付規定」(更新日 2026-05-31)· 實證補充段:人工彙整。 本頁為資訊整理,實際給付與適應症以主管機關公告為準。